Edward P. Acosta
Affiliations: | University of Alabama, Birmingham, Birmingham, AL, United States |
Area:
Pharmacology, Pharmaceutical ChemistryWebsite:
http://apps.medicine.uab.edu/FacultyDirectory/FacultyData.asp?FID=7143Google:
"Edward P. Acosta"Mean distance: (not calculated yet)
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Li JZ, Melberg M, Kittilson A, et al. (2024) Predictors of HIV rebound differ by timing of antiretroviral therapy initiation. Jci Insight. 9 |
| Chandasana H, Thapar M, Hayes S, et al. (2023) Population Pharmacokinetic Modeling of Dolutegravir to Optimize Pediatric Dosing in HIV-1-Infected Infants, Children, and Adolescents. Clinical Pharmacokinetics |
| Brooks KM, Kiser JJ, Ziemba L, et al. (2023) Pharmacokinetics, safety, and tolerability of dispersible and immediate-release abacavir, dolutegravir, and lamivudine tablets in children with HIV (IMPAACT 2019): week 24 results of an open-label, multicentre, phase 1-2 dose-confirmation study. The Lancet. Hiv. 10: e506-e517 |
| McMahon DK, Zheng L, Cyktor JC, et al. (2021) A Phase 1/2 Randomized, Placebo-Controlled Trial of Romidespin in Persons With HIV-1 on Suppressive Antiretroviral Therapy. The Journal of Infectious Diseases. 224: 648-656 |
| McMahon DK, Zheng L, Cyktor JC, et al. (2020) A phase I/II randomized, placebo-controlled trial of romidepsin in persons with HIV-1 on suppressive antiretroviral therapy to assess safety and activation of HIV-1 expression (A5315). The Journal of Infectious Diseases |
| Clarke DF, Lommerse J, Acosta EP, et al. (2020) IMPACT OF LOW BIRTH WEIGHT AND PREMATURITY ON NEONATAL RALTEGRAVIR PHARMACOKINETICS: IMPAACT P1097. Journal of Acquired Immune Deficiency Syndromes (1999) |
| Krogstad P, Samson P, Acosta EP, et al. (2020) Pharmacokinetics and Safety of a Raltegravir-Containing Regimen in Children Aged 4 Weeks to 2 Years Living With Human Immunodeficiency Virus and Receiving Rifampin for Tuberculosis. Journal of the Pediatric Infectious Diseases Society |
| Bull M, Mitchell C, Soria J, et al. (2020) Genital shedding of human immunodeficiency virus type-1 (HIV) when antiretroviral therapy (ART) suppresses HIV replication in the plasma. The Journal of Infectious Diseases |
| Acosta E, Bowlin T, Brooks J, et al. (2020) Advances in the Development of Therapeutics for Cytomegalovirus Infections. The Journal of Infectious Diseases. 221: S32-S44 |
| Guimbellot JS, Ryan KJ, Anderson JD, et al. (2020) Variable cellular ivacaftor concentrations in people with cystic fibrosis on modulator therapy. Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society |